OpenAI has introduced GPT-Rosalind, a reasoning model for life sciences research, with a focus on biology, drug discovery, and translational medicine.
The model is available as a research preview to qualified enterprise users in the United States through a controlled-access programme, and can be used via ChatGPT, Codex, and the API.
The model is named after Rosalind Franklin, whose work contributed to the discovery of DNA’s structure.
OpenAI said this is the first release in a planned series of domain-specific life sciences models, with future work set to improve biological reasoning and expand support for complex research workflows.
The company said the model is built to support scientific workflows such as literature review, hypothesis generation, experimental planning, and data analysis. It aims to help researchers work across large datasets, scientific literature, and specialised tools to improve early-stage discovery.
“We believe advanced AI systems can help researchers move through these workflows faster—not just by making existing work more efficient, but by helping scientists explore more possibilities,” the company said.
OpenAI said that drug development typically takes 10 to 15 years from discovery to regulatory approval in the US, and argued that improvements in early research stages can affect downstream outcomes such as target selection and experimental quality.
GPT-Rosalind has been tested across benchmarks in chemistry, protein understanding, genomics, and experimental design.
OpenAI said GPT-Rosalind integrates with scientific tools and databases. It is launching alongside a Life Sciences research plugin for Codex that connects to more than 50 public datasets and tools across genomics, protein research, and clinical data.
The model is being tested with organisations including Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
Access to the model is limited under a trusted access system. Organisations must demonstrate that they are conducting legitimate research and follow safety and governance rules.
OpenAI said use during the preview phase will not count against standard credits, with safeguards in place.
Your reaction
Discussion
What's your take on this story?
No comments yet — be the first to share your view.